- Home
- FCO vs ATOS Comparison
FCO vs ATOS Comparison
Compare FCO & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCO | ATOS |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 36.2M |
| IPO Year | 1994 | 2010 |
Fundamental Metrics
Financial Performance| Metric | FCO | ATOS |
|---|---|---|
| Price | $3.23 | $5.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.67 |
| AVG Volume (30 Days) | ★ 140.2K | 75.4K |
| Earning Date | 01-01-0001 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.73 | $0.53 |
| 52 Week High | $6.77 | $7.56 |
Technical Indicators
Market Signals| Indicator | FCO | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 66.62 |
| Support Level | $3.18 | $0.68 |
| Resistance Level | $3.26 | $7.56 |
| Average True Range (ATR) | 0.08 | 0.43 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 71.79 | 65.87 |
Price Performance
Historical ComparisonAbout FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories: Developed Markets, Investment Grade Developing Markets, and Sub-Investment Grade Developing Markets.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.